Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Excluding the Pending Study 2 Data on 27 patients

<< Previous

Bullboard Posts

Next >>

Comment by gojotv!on Aug 31, 2021 11:35am

154 Views

Post# 33787862

RE:RE:Excluding the Pending Study 2 Data on 27 patients

See what I mean, guys? The newbies just aren't getting it, even after pages of discussion... Here you go, "Biggainer",...
This is from a few pages back.

gojotv! (1165)

August 31, 2021 - 05:24 AM

224 Reads

Post# 33786616

RE:Prelim Results

You're not reading that graph right, monte.
The results aren't "down to 11.1 for 360 days and 450". The results for the totality of patients are largely PENDING for days 360 and 450, because most patients weren't treated that long ago, or their results aren't fully analyzed yet.
So, yeah, when you see the very robust duration of this treatment's efficacy, it's very exciting news! 33% complete response after only one to two simple outpatient treatments...?! That's amazing!
Nearly half of patients SO FAR have achieved strong, positive pushback on their cancer... could be more... results are pending.
Which points to TLT's future commercial success, since nothing prevents these patients from trying again until they have the desired response. Third or fourth treatments...?! Why not? The safety is unparallelled.
This shows every sign of being the game-changer that oncologists have been searching for...
Go, TLT, go!

monte2016 wrote:There is a graph with incomplete prelim results. For those that are experienced in these biotech plays...what is your opinion on these results? 90 day shows 33.3 CR and that is down to 11.1 for 360 days and 450. Are these numbers high enough for CR to excite the medical community? Your thoughts would be appreciated. Thanks.

Reply

Quote

Biggainer wrote: I don't know if these are great numbers. from what you got that's a quite a drop from 90 days cr+pr to 450 days cr+pr.

cashascars wrote: Here is my math when you exclude the Pending and only include the examined patients at each interval.

90 days---- 61.9% CR+PR
180 days---55.5% CR+PR
270 days---41.2% CR+PR
360 days---37.5% CR+PR
450 days----28.6% CR+PR

And as you know the numbers will only get better because the original 12 undertreated
are incuded in this calculation.

These are great numbers and for the simplicity of the procedure we are on our way to becomeing the gold standard baby!
All this is in my own head and that could be the only problem.
cashascars